Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00353496 · ClinicalTrials.gov registry record · Phase 3
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
A Phase 3 study, sponsored by Ipsen.
- Completed
- Registry status
- Phase 3
- Development phase
- 264
- Enrollment target
NCT00353496 is a Phase 3 study that has completed, run by Ipsen. The registered enrollment target is 264 participants.
The verdict
NCT00353496, a Phase 3 study, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 264 participants
- Enrollment target
Study Summary
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Interventions
- DRUG Placebo
- DRUG lanreotide (Autogel formulation)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 264 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00353496
The ClinicalTrials.gov registry entry for NCT00353496 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 264 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00353496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00353496 about?
NCT00353496 is a clinical study titled "Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours". The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
What is the current status of trial NCT00353496?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 264 participants. The study started on 2006-06. Estimated completion is 2013-04.
What interventions are being tested in trial NCT00353496?
The interventions under investigation include: Placebo (DRUG), lanreotide (Autogel formulation) (DRUG).
Who is sponsoring clinical trial NCT00353496?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.